Neutrophil kinetics in health and disease

Charlotte Summers, Sara M Rankin, Alison M Condliffe, Nanak Singh, A Michael Peters, Edwin R Chilvers, Charlotte Summers, Sara M Rankin, Alison M Condliffe, Nanak Singh, A Michael Peters, Edwin R Chilvers

Abstract

Neutrophils play a key role in the elimination of pathogens. They are remarkably short-lived with a circulating half life of 6-8h and hence are produced at a rate of 5x10(10)-10x10(10) cells/day. Tight regulation of these cells is vital because they have significant histotoxic capacity and are widely implicated in tissue injury. This review outlines our current understanding of how neutrophils are released from the bone marrow; in particular, the role of the CXC chemokine receptor 4/stromal-derived factor 1 axis, the relative size and role of the freely circulating and marginated (i.e. slowly transiting) pools within the vascular compartment, and the events that result in the uptake and removal of circulating neutrophils. We also review current understanding of how systemic stress and inflammation affect this finely balanced system.

2010 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Factors that affect the size of the marginated and circulating granulocyte pools. G-CSF is the principal regulator of granulopoiesis and affects the commitment of progenitor cells to the myeloid lineage, proliferation of granulocytic precursors, as well as reducing transit time through the granulocyte compartment and stimulating the release of mature cells from the bone marrow. Neutrophil release from the bone marrow into the total blood granulocyte pool reflects loss of interaction between CXCR4 and SDF-1, and between VLA-4 and VCAM-1. Neutrophils within the total blood pool then enter either the marginated or freely circulating granulocyte pool that are of similar size in humans. A number of factors including exercise, drugs and infection affect the relative size of these two pools, as indicated.
Figure 2
Figure 2
Physiological fate of granulocytes within the blood pool. The absence of infection or injury (which results in the targeted migration of neutrophils into the inflamed tissues), neutrophils exit the total blood granulocyte pool and can be found in the liver, spleen and bone marrow in approximately equal proportions. Neutrophil apoptosis within these tissues results in macrophage recognition and ingestion that leads to G-CSF generation, which in turn stimulates granulopoiesis. Neutrophils within inflamed tissue undergo apoptotic or necrotic cell death or are lost to the body following trans-epithelial migration.
Figure 3
Figure 3
Effects of local and systemic inflammation on neutrophil kinetics. Tissue inflammation results in the release of multiple inflammatory mediators and subsequent neutrophil priming. Priming results in a marked change in neutrophil shape and rheology that leads to retention within the capillary microvascular bed of the lung. The liver is thought to play a particularly important role in recognizing and removing damaged neutrophils. Circulating inflammatory markers stimulate granulopoiesis and rapid release of preformed mature neutrophils from the bone marrow.

References

    1. Sasmono R.T. Mouse neutrophilic granulocytes express mRNA encoding the macrophage colony-stimulating factor receptor (CSF-1R) as well as many other macrophage-specific transcripts and can transdifferentiate into macrophages in vitro in response to CSF-1. J. Leukoc. Biol. 2007;82:111–123.
    1. Gomez J.C. The role of Rac2 in regulating neutrophil production in the bone marrow and circulating neutrophil counts. Am. J. Pathol. 2008;173:507–517.
    1. Friedman A.D. Transcriptional regulation of granulocyte and monocyte development. Oncogene. 2002;21:3377–3390.
    1. Rosmarin A.G. Transcriptional regulation in myelopoiesis: hematopoietic fate choice, myeloid differentiation, and leukemogenesis. Exp. Hematol. 2005;33:131–143.
    1. Athens J.W. Blood: leukocytes. Annu. Rev. Physiol. 1963;25:195–212.
    1. Dancey J.T. Neutrophil kinetics in man. J. Clin. Invest. 1976;58:705–715.
    1. Athens J.W. Leukokinetic studies. IV. The total blood, circulating and marginal granulocyte pools and the granulocyte turnover rate in normal subjects. J. Clin. Invest. 1961;40:989–995.
    1. Cartwright G.E. The kinetics of granulopoiesis in normal man. Blood. 1964;24:780–803.
    1. DONOHUE D.M. Quantitative measurement of the erythrocytic and granulocytic cells of the marrow and blood. J. Clin. Invest. 1958;37:1571–1576.
    1. Richards M.K. Pivotal role of granulocyte colony-stimulating factor in the development of progenitors in the common myeloid pathway. Blood. 2003;102:3562–3568.
    1. Lord B.I. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc. Natl. Acad. Sci. U. S. A. 1989;86:9499–9503.
    1. Lieschke G.J. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood. 1994;84:1737–1746.
    1. Liu F. Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Immunity. 1996;5:491–501.
    1. Sinha S. Deletional mutation of the external domain of the human granulocyte colony-stimulating factor receptor in a patient with severe chronic neutropenia refractory to granulocyte colony-stimulating factor. J. Pediatr. Hematol. Oncol. 2003;25:791–796.
    1. Druhan L.J. Novel mechanism of G-CSF refractoriness in patients with severe congenital neutropenia. Blood. 2005;105:584–591.
    1. Pojda Z., Tsuboi A. In vivo effects of human recombinant interleukin 6 on hemopoietic stem and progenitor cells and circulating blood cells in normal mice. Exp. Hematol. 1990;18:1034–1037.
    1. Metcalf D. Hemopoietic responses in mice injected with purified recombinant murine GM-CSF. Exp. Hematol. 1987;15:1–9.
    1. Metcalf D. Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood. 1986;68:46–57.
    1. Kopf M. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368:339–342.
    1. Stanley E. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc. Natl. Acad. Sci. U. S. A. 1994;91:5592–5596.
    1. Nishinakamura R. Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions. Blood. 1996;88:2458–2464.
    1. Walker F. IL6/sIL6R complex contributes to emergency granulopoietic responses in G-CSF- and GM-CSF-deficient mice. Blood. 2008;111:3978–3985.
    1. Campbell F.R. Ultrastructural studies of transmural migration of blood cells in the bone marrow of rats, mice and guinea pigs. Am. J. Anat. 1972;135:521–535.
    1. Weiss L. Transmural cellular passage in vascular sinuses of rat bone marrow. Blood. 1970;36:189–208.
    1. Burdon P.C. Migration across the sinusoidal endothelium regulates neutrophil mobilization in response to ELR + CXC chemokines. Br. J. Haematol. 2008;142:100–108.
    1. Hubel K. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. J. Infect. Dis. 2002;185:1490–1501.
    1. Zuelzer W.W. Myelokathexis”—a new form of chronic granulocytopenia. Report of a case. N. Engl. J. Med. 1964;270:699–704.
    1. Hernandez P.A. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat. Genet. 2003;34:70–74.
    1. Gorlin R.J. WHIM syndrome, an autosomal dominant disorder: clinical, hematological, and molecular studies. Am. J. Med. Genet. 2000;91:368–376.
    1. Ma Q. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity. 1999;10:463–471.
    1. Devine S.M. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4-SDF-1 interaction. Blood. 2008;112:990–998.
    1. Iyer C.V. Rapid and recurrent neutrophil mobilization regulated by T134, a CXCR4 peptide antagonist. Exp. Hematol. 2008;36:1098–1109.
    1. Pelus L.M. The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor. Exp. Hematol. 2005;33:295–307.
    1. Cashen A.F. Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells. Drugs Today (Barc.) 2009;45:497–505.
    1. De C.E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil) Biochem. Pharmacol. 2009;77:1655–1664.
    1. Semerad C.L. G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity. 2002;17:413–423.
    1. Kim H.K. G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood. 2006;108:812–820.
    1. Link D.C. Neutrophil homeostasis: a new role for stromal cell-derived factor-1. Immunol. Res. 2005;32:169–178.
    1. Petty J.M. Crosstalk between CXCR4/stromal derived factor-1 and VLA-4/VCAM-1 pathways regulates neutrophil retention in the bone marrow. J. Immunol. 2009;182:604–612.
    1. MAUER A.M. Leukokinetic studies. II. A method for labeling granulocytes in vitro with radioactive diisopropylfluorophosphate (DFP) J. Clin. Invest. 1960;39:1481–1486.
    1. Athens J.W. Leukokinetic studies. III. The distribution of granulocytes in the blood of normal subjects. J. Clin. Invest. 1961;40:159–164.
    1. Peters A.M. Splenic pooling of granulocytes. Clin. Sci. (Lond.) 1985;68:283–289.
    1. Ussov W.Y. Granulocyte margination in bone marrow: comparison with margination in the spleen and liver. Scand. J. Clin. Lab Invest. 1995;55:87–96.
    1. Hogg J.C., Doerschuk C.M. Leukocyte traffic in the lung. Annu. Rev. Physiol. 1995;57:97–114.
    1. Peters A.M. Just how big is the pulmonary granulocyte pool? Clin. Sci. (Lond.) 1998;94:7–19.
    1. Suratt B.T. Neutrophil maturation and activation determine anatomic site of clearance from circulation. Am. J. Physiol. Lung Cell Mol. Physiol. 2001;281:L913–L921.
    1. Saverymuttu S.H. The kinetics of 111indium distribution following injection of 111indium labelled autologous granulocytes in man. Br. J. Haematol. 1985;61:675–685.
    1. Furze R.C., Rankin S.M. The role of the bone marrow in neutrophil clearance under homeostatic conditions in the mouse. FASEB J. 2008;22:3111–3119.
    1. Martin C. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity. 2003;19:583–593.
    1. Nagase H. Cytokine-mediated regulation of CXCR4 expression in human neutrophils. J. Leukoc. Biol. 2002;71:711–717.
    1. Ma Q. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in C. Proc. Natl. Acad. Sci. U. S. A. 1998;95:9448–9453.
    1. Eash K.J. CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. Blood. 2009;113:4711–4719.
    1. Shi J. Role of the liver in regulating numbers of circulating neutrophils. Blood. 2001;98:1226–1230.
    1. Terashima T. Release of polymorphonuclear leukocytes from the bone marrow by interleukin-8. Blood. 1998;92:1062–1069.
    1. Wengner A.M. The coordinated action of G-CSF and ELR + CXC chemokines in neutrophil mobilization during acute inflammation. Blood. 2008;111:42–49.
    1. Petty J.M. Pulmonary stromal-derived factor-1 expression and effect on neutrophil recruitment during acute lung injury. J. Immunol. 2007;178:8148–8157.
    1. Condliffe A.M. Neutrophil priming: pathophysiological consequences and underlying mechanisms. Clin. Sci. (Lond) 1998;94:461–471.
    1. Guthrie L.A. Priming of neutrophils for enhanced release of oxygen metabolites by bacterial lipopolysaccharide. Evidence for increased activity of the superoxide-producing enzyme. J. Exp. Med. 1984;160:1656–1671.
    1. Worthen G.S. Neutrophil-mediated pulmonary vascular injury. Synergistic effect of trace amounts of lipopolysaccharide and neutrophil stimuli on vascular permeability and neutrophil sequestration in the lung. Am. Rev. Respir. Dis. 1987;136:19–28.
    1. Kitchen E. Demonstration of reversible priming of human neutrophils using platelet-activating factor. Blood. 1996;88:4330–4337.
    1. Ussov W.Y. Pulmonary granulocyte kinetics in relation to endothelial and granulocyte activation. Clin. Sci. (Lond.) 1999;96:525–531.
    1. Ussov W.Y. Relationship between granulocyte activation, pulmonary granulocyte kinetics and alveolar permeability in extrapulmonary inflammatory disease. Clin. Sci. (Lond.) 1996;91:329–335.
    1. Nahum A. Differential activation of mixed venous and arterial neutrophils in patients with sepsis syndrome and acute lung injury. Am. Rev. Respir. Dis. 1991;143:1083–1087.
    1. Yoshida K. Neutrophil cytoskeletal rearrangements during capillary sequestration in bacterial pneumonia in rats. Am. J. Respir. Crit. Care Med. 2006;174:689–698.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner